I-Mab Raises $65 Million to Advance Givastomig Phase 2 Trial for Gastric Cancer
核心洞察
I-Mab (搜索) completed a $65 million underwritten offering of American Depositary Shares at $1.95 per share to fund clinical development programs.
The proceeds will primarily support a randomized Phase 2 trial of givastomig, a bispecific Claudin 18.2 (搜索) x 4-1BB (搜索) antibody for gastric cancer (搜索) treatment.
Givastomig has demonstrated strong tumor-binding and anti-tumor activity in Phase 1 trials while minimizing toxicities associated with other 4-1BB (搜索) agents.
I-Mab (搜索), a U.S.-based global biotech company focused on precision immuno-oncology agents, announced the successful pricing of a $65 million underwritten offering to advance its lead drug candidate givastomig through Phase 2 clinical development. The company priced 33,333,334 American Depositary Shares at $1.95 per ADS, with the offering expected to close on August 5, 2025.
Funding to Support Pivotal Gastric Cancer Trial
The net proceeds from the offering will primarily fund ongoing clinical development of I-Mab (搜索)'s pipeline product candidates, with particular focus on a randomized Phase 2 trial of givastomig. This bispecific Claudin 18.2 (搜索) x 4-1BB (搜索) antibody is designed to treat Claudin 18.2-positive gastric cancers and represents the company's most advanced therapeutic candidate.
The planned Phase 2 trial is intended to have sufficient power and size to generate clinically meaningful progression-free survival (PFS) data by the end of 2027. This timeline positions I-Mab (搜索) to potentially advance givastomig toward late-stage development and regulatory approval within the next few years.
Promising Early Clinical Results
Givastomig has shown encouraging results in ongoing Phase 1 trials, demonstrating strong tumor-binding and anti-tumor activity. The company attributes this efficacy to a potential synergistic effect of proximal interaction between Claudin 18.2 (搜索) and 4-1BB (搜索) pathways. Importantly, givastomig has been observed to minimize toxicities commonly associated with other 4-1BB agents, addressing a key safety concern in this therapeutic class.
The drug works by conditionally activating T cells via the 4-1BB (搜索) signaling pathway specifically in the tumor microenvironment where Claudin 18.2 (搜索) is expressed. This targeted approach is designed to enhance anti-tumor immune responses while reducing systemic toxicity.
Broad Investor Support
The offering attracted participation from both new and existing investors, including notable institutional investors such as Everest Medicines (搜索), Janus Henderson Investors (搜索), Adage Capital Partners LP (搜索), and Exome Asset Management (搜索). Leerink Partners (搜索) served as the lead bookrunning manager, with BTIG (搜索) acting as bookrunning manager and Lucid Capital Markets (搜索) as lead manager.
Therapeutic Focus and Market Opportunity
Givastomig is being developed primarily for first-line metastatic gastric cancers, with additional potential applications in other solid tumors (搜索). The company describes givastomig as a potential best-in-class bispecific antibody, positioning it to compete in the growing immuno-oncology market.
I-Mab (搜索)'s differentiated pipeline centers on precision immuno-oncology agents designed to treat various cancer (搜索) types. The company's approach focuses on developing therapies that can effectively target specific tumor characteristics while maintaining favorable safety profiles.
The funding will also support working capital and other general corporate purposes as I-Mab (搜索) continues to advance its clinical programs and build its position in the competitive oncology therapeutics space.